The Novartis dispute with India over patent rights for its Glivec anti-cancer drug has been referred directly to the country's two-day-old patent appeals board. The board is to serve as the highest court determining patents in India, but Novartis notes the board's technical expert was controller general of the Indian Patent Office when it first rejected the Glivec patent last year.

Full Story:

Related Summaries